Initiated the global Phase 2 study of NTLA-2002, a CRISPR-based, potential single-dose treatment for hereditary angioedema (HAE)Submitted IND application for...
–Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) continues to have high operating fidelity; month 30...
– Initiated multiple trials with ARV-471, including a 2L+ Phase 3 trial for patients with metastatic breast cancer – – Presented Phase...
CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna”), a preclinical-stage biotechnology company committed to...
Company retains 30% stake while eliminating operating expense and future development obligations Represents next step in plan to focus product...
Monday, February 27th at 10am ETMADRID, Spain and BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code:...
BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively...
In vitro and in vivo results demonstrated HC-7366 is a potent GCN2 activator with strong antitumor activity in AML as...
BOSTON, MASSACHUSETTS, Feb. 22, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing...
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Feb. 21, 2023...
BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that a review of initial data from...
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ETSOUTH SAN FRANCISCO, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) --...
Results presented at 30th Conference on Retroviruses and Opportunistic Infections (CROI)SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 21, 2023...
WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology...
CAMBRIDGE, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering...
MONTRÉAL, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Esperas Pharma, Inc. (“Esperas”), a company based in Montréal, Québec, today announced a...
SAN DIEGO, Feb. 18, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted an IRS Form 8937...
Rehovot, Israel, Feb. 17, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company”) announced today that...
OCALA, Fla., Feb. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma...
Both Fanconi Anemia patients treated with briquilimab successfully engrafted with neutrophil engraftment within 11 days100% total donor chimerism was achieved...